logo     Print Page | Close Window

Overview

BPMC (Common Stock) $41.01 Stock is Down 0.03 (0.00%)
Volume274,139
03/23/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15
minutes delay
Refresh quote

Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.Read More

Upcoming Events

There are currently no events scheduled.

View More

Presentation

January 2017 Blueprint Medicines – Investor Presentation